Expert Interviews

Michael Rubio, PA-C, and Renata Block, MMS, PA-C discuss the complexities associated with practicing telemedicine, especially as a PA.

The panelist discusses how a 35-year-old man with atopic dermatitis requires personalized, comprehensive management considering skin of color complexities, focusing on trigger identification, targeted therapies like dupilumab, and holistic approach to inflammation, skin barrier protection, and aesthetic concerns.

Panelists discuss the unique challenges of managing atopic dermatitis in children compared with adults, focusing on factors such as skin barrier differences, treatment adherence, and the impact on growth and development.

The panelist discusses how an 8-year-old girl with moderate to severe atopic dermatitis requires a comprehensive treatment approach focusing on dupilumab as a potential systemic therapy. Treatment goals include reducing inflammation, improving quality of life, and providing age-appropriate, empathetic care while addressing patient and caregiver concerns about efficacy and safety.

Panelists discuss the mental and physical burden of atopic dermatitis on pediatric patients and their caregivers and share approaches to addressing the psychosocial impact of the condition, highlighting how these factors influence treatment selection and care strategies.

Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.

Michael Rubio, PA-C talks with Renata Block, MMS, PA-C, about his virtual care platform and how it can expand access to care.

Renata Block, MMS, PA-C, and Michael Rubio, PA-C discuss the complexities of developing a telehealth program in the world of dermatology.

Catch up on coverage from the 2025 South Beach Symposium held in Miami Beach, Florida.

Panelists discuss how atopic dermatitis is linked to other type 2 inflammatory conditions in the pediatric population, exploring the shared immune pathways and comorbidities that connect these disorders.

Panelists discuss the pathophysiology of atopic dermatitis, highlighting the role of type 2 inflammation in driving the disease process and explaining how this inflammation contributes to the characteristic itch-scratch cycle seen in affected individuals.

The panelist discusses how systemic atopic dermatitis (AD) treatment involves biologics and Janus kinase inhibitors for moderate to severe cases, targeting inflammation and itch with individualized approach based on patient factors, offering significant symptom improvement and skin barrier restoration.

The panelist discusses how atopic dermatitis is a complex chronic skin condition causing significant physical and psychological burden, challenging patients and clinicians through multifaceted management requiring personalized, holistic approaches.

Lio emphasizes that patient comfort and understanding are essential for successful treatment outcomes.

Many patients, especially parents of pediatric patients, exhibit steroid phobia, impacting treatment adherence.

Swanson shared strategies for treating rural dermatology patients at MOPD 2025, emphasizing effective initial care, the role of telehealth, and practical treatments.

Corey Hartman, MD, FAAD, discusses how incorporating proper pre- and posttreatment protocols along with topical agents maximizes patient comfort and enhances treatment outcomes in laser therapy for pigmentary conditions.

A panelist discusses how using conservative laser settings, proper skin cooling, and careful patient selection is crucial when treating melasma and darker skin types to minimize post-inflammatory hyperpigmentation risks.

Corey Hartman, MD, FAAD, discusses how combining multiple laser modalities with proper patient education and realistic expectations leads to optimal outcomes when treating hyperpigmentation and other pigmentary disorders.

Long-term safety data suggests that JAK inhibitors have a lower risk of cardiovascular and thromboembolic events than previously thought.

Medical and aesthetic dermatologists partner at SBS 2025 to bridge gaps between clinical care and cosmetic procedures.

Michael Gold, MD, explored microneedling innovations, pulse wave technology for pigmentation, and the aesthetic effects of GLP-1 receptor agonists, including "Ozempic face" and skin laxity.

Compliance with acne medications remains a challenge, but timely intervention can prevent severe skin damage.

Mona Shahriari, MD, FAAD advocates for improving diversity in clinical imagery and trials to enhance trust in patients with skin of color.

A holistic yet time-efficient approach can help dermatologists recognize early joint pain symptoms associated with psoriasis.

A balanced approach to dermatologic care involves using steroids for flare-ups and switching to non-steroidal options for maintenance.

Chilukuri said devices should be user-friendly even in solo practice settings to maximize efficiency and usability.

Michael Gold, MD, explored medical and procedural acne treatments and the emerging role of exosomes in regenerative dermatology.

Traditional descriptions often cater to lighter skin, necessitating updates to better serve diverse populations.

Advanced wound healing techniques, including exosomes and polynucleotides, can enhance post-procedure recovery and reduce pigmentation issues.